Trulieve Cannabis
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical marijuana company. The last earnings update was 49 days ago. More info.
Add to Portfolio Compare Print
- Trulieve Cannabis has significant price volatility in the past 3 months.
TRUL Share Price and Events
7 Day Returns
1 Year Returns
TRUL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Trulieve Cannabis (TRUL) | -1.7% | 0.4% | -27.5% | - | - | - |
| CA Pharmaceuticals | -9.9% | -11.6% | -25.7% | -7.6% | 508.2% | 385.5% |
| CA Market | -0.4% | 0.8% | -1.7% | -3.1% | 8.2% | 0.9% |
1 Year Return vs Industry and Market
- No trading data on TRUL.
- No trading data on TRUL.
TRUL Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Trulieve Cannabis
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Trulieve Cannabis.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 5 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7% |
| Perpetual Growth Rate | 10-Year CA Government Bond Rate | 1.9% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CA Govt Bond Rate | 1.9% |
| Equity Risk Premium | S&P Global | 6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.73 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 21%) (4.69%)) |
0.839 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.84 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.839 * 5.96%) |
6.95% |
Discounted Cash Flow Calculation for CNSX:TRUL using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Trulieve Cannabis is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 6.95%) |
|
|---|---|---|---|
| 2020 | 72.56 | Analyst x2 | 67.84 |
| 2021 | 98.83 | Analyst x1 | 86.40 |
| 2022 | 120.62 | Est @ 22.06% | 98.60 |
| 2023 | 139.95 | Est @ 16.02% | 106.97 |
| 2024 | 156.47 | Est @ 11.8% | 111.82 |
| 2025 | 170.31 | Est @ 8.84% | 113.80 |
| 2026 | 181.85 | Est @ 6.78% | 113.61 |
| 2027 | 191.54 | Est @ 5.33% | 111.89 |
| 2028 | 199.80 | Est @ 4.31% | 109.13 |
| 2029 | 207.00 | Est @ 3.6% | 105.72 |
| Present value of next 10 years cash flows | $1,025.78 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2029
× (1 + g) ÷ (Discount Rate – g)
= $207.00 × (1 + 1.95%) ÷ (6.95% – 1.95%) |
$4,217.66 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $4,217.66 ÷ (1 + 6.95%)10 |
$2,154.01 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $1,025.78 + $2,154.01 |
$3,179.79 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $3,179.79 / 110.13 |
$28.87 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | USD/CAD
(Reporting currency to currency of CNSX:TRUL) |
1.305 |
| Value per Share (CAD) |
= Value per Share in USD x Exchange Rate (USD/CAD)
= $28.87 x 1.305 |
CA$37.67 |
| Value per share (CAD) | From above. | CA$37.67 |
| Current discount | Discount to share price of
CA$13.55
= -1 x (CA$13.55 - CA$37.67) / CA$37.67 |
64% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Trulieve Cannabis's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Trulieve Cannabis's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Trulieve Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Trulieve Cannabis's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $0.49 |
| CNSX:TRUL Share Price ** | CNSX (2019-07-15) in CAD | CA$13.55 |
| CNSX:TRUL Share Price converted to USD reporting currency | Exchange rate (CAD/ USD) 0.767 | $10.39 |
| Canada Pharmaceuticals Industry PE Ratio | Median Figure of 11 Publicly-Listed Pharmaceuticals Companies | 18.21x |
| Canada Market PE Ratio | Median Figure of 539 Publicly-Listed Companies | 15x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Trulieve Cannabis.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = CNSX:TRUL Share Price ÷ EPS (both in USD) = 10.39 ÷ 0.49 |
21.38x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Trulieve Cannabis is overvalued based on earnings compared to the CA Pharmaceuticals industry average.
- Trulieve Cannabis is overvalued based on earnings compared to the Canada market.
Price based on expected Growth
Does
Trulieve Cannabis's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 21.38x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
35.8%per year |
| Canada Pharmaceuticals Industry PEG Ratio | Median Figure of 7 Publicly-Listed Pharmaceuticals Companies | 1.11x |
| Canada Market PEG Ratio | Median Figure of 249 Publicly-Listed Companies | 1.16x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 21.38x ÷ 35.8% |
0.6x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Trulieve Cannabis is good value based on expected growth next year.
Price based on value of assets
What value do investors place on
Trulieve Cannabis's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.07 |
| CNSX:TRUL Share Price * | CNSX (2019-07-15) in CAD | CA$13.55 |
| CNSX:TRUL Share Price converted to USD reporting currency | Exchange rate (CAD/ USD) 0.767 | $10.39 |
| Canada Pharmaceuticals Industry PB Ratio | Median Figure of 144 Publicly-Listed Pharmaceuticals Companies | 2.21x |
| Canada Market PB Ratio | Median Figure of 2,436 Publicly-Listed Companies | 1.42x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = CNSX:TRUL Share Price ÷ Book Value per Share (both in USD) = 10.39 ÷ 1.07 |
9.69x |
* Primary Listing of Trulieve Cannabis.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Trulieve Cannabis is overvalued based on assets compared to the CA Pharmaceuticals industry average.
Value checks
We assess Trulieve Cannabis's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Trulieve Cannabis has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
TRUL Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Trulieve Cannabis's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
- Trulieve Cannabis's earnings growth is expected to exceed the Canada market average.
- Trulieve Cannabis's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| CNSX:TRUL Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | 35.8% |
| CNSX:TRUL Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 41.6% |
| Canada Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 97.2% |
| Canada Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 53.2% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 5.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 470 | 147 | 2 | |
| 2020-12-31 | 389 | 39 | 97 | 5 |
| 2019-12-31 | 235 | 11 | 70 | 5 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 132 | 34 | 51 |
| 2018-12-31 | 103 | 25 | 43 |
| 2018-09-30 | 80 | 19 | 33 |
| 2018-06-30 | 55 | 10 | 16 |
| 2018-03-31 | 33 | 2 | 9 |
| 2017-12-31 | 20 | 0 | 4 |
| 2016-12-31 | 0 | -4 | -4 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from Trulieve Cannabis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 1.34 | 1.34 | 1.34 | 1.00 |
| 2020-12-31 | 0.85 | 1.09 | 0.71 | 4.00 |
| 2019-12-31 | 0.62 | 0.73 | 0.47 | 4.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 0.49 |
| 2018-12-31 | 0.42 |
| 2018-09-30 | 0.30 |
| 2018-06-30 | 23.63 |
| 2018-03-31 | 0.09 |
| 2017-12-31 | 0.05 |
| 2016-12-31 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Trulieve Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Trulieve Cannabis's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Trulieve Cannabis has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
TRUL Past Performance
How has Trulieve Cannabis performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Insufficient data to establish if Trulieve Cannabis's year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Trulieve Cannabis's 1-year earnings growth to the 5-year average due to insufficient past data.
- Trulieve Cannabis's earnings growth has exceeded the CA Pharmaceuticals industry average in the past year (461.4% vs 22.3%).
Earnings and Revenue History
All data from Trulieve Cannabis Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 132.05 | 50.81 | 36.41 | |
| 2018-12-31 | 102.82 | 42.97 | 29.19 | |
| 2018-09-30 | 80.11 | 32.59 | 22.85 | |
| 2018-06-30 | 55.16 | 15.55 | 17.03 | |
| 2018-03-31 | 33.44 | 9.05 | 11.99 | |
| 2017-12-31 | 19.78 | 3.57 | 8.31 | |
| 2016-12-31 | 0.16 | -3.66 | 1.46 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Trulieve Cannabis made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
- Trulieve Cannabis used its assets more efficiently than the CA Pharmaceuticals industry average last year based on Return on Assets.
- Unable to establish if Trulieve Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
Past performance checks
We assess Trulieve Cannabis's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Trulieve Cannabis has a total score of 3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
TRUL Health
How is Trulieve Cannabis's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Trulieve Cannabis's finances.
The net worth of a company is the difference between its assets and liabilities.
- Trulieve Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Trulieve Cannabis's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 4.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Trulieve Cannabis Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 118.06 | 20.01 | 20.58 |
| 2018-12-31 | 104.22 | 20.07 | 24.43 |
| 2018-09-30 | 91.99 | 19.89 | 42.14 |
| 2018-06-30 | 26.10 | 32.10 | 8.87 |
| 2018-03-31 | 11.12 | 14.46 | 1.41 |
| 2017-12-31 | 11.12 | 14.46 | 1.41 |
| 2016-12-31 | -0.06 | 5.44 | 0.14 |
- Trulieve Cannabis's level of debt (16.9%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Trulieve Cannabis's debt level has increased without past 5-year debt data.
- Debt is well covered by operating cash flow (169.5%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 29.5x coverage).
Financial health checks
We assess Trulieve Cannabis's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Trulieve Cannabis has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
TRUL Dividends
What is Trulieve Cannabis's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Trulieve Cannabis
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Trulieve Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Trulieve Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| North America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 2.8% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 336 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2.1% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Trulieve Cannabis has not reported any payouts.
- Unable to verify if Trulieve Cannabis's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Trulieve Cannabis's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Trulieve Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Trulieve Cannabis has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
TRUL Management
CEO
| COMPENSATION | $150,000 |
| AGE | 40 |
| TENURE AS CEO | 4.1 years |
CEO Bio
Ms. Kimberly Rivers, also known as Kim, serves as Chairman and Chief Executive Officer of Trulieve Cannabis Corp. and has been its Director since November 2015. Ms. Rivers is a member of the Georgia Bar association and she spent several years in private practice as a lawyer where she specialized in mergers, acquisitions, and securities for multi-million dollar companies. For over a decade, Ms. Rivers has run numerous successful businesses from real estate to finance. Ms. Rivers received her Bachelor's degree in Multinational Business and Political Science from Florida State University and her Juris Doctorate from the University of Florida.
CEO Compensation
- Insufficient data for Kim to compare compensation growth.
- Kim's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure and age of the Trulieve Cannabis management team in years:
- The average tenure for the Trulieve Cannabis management team is less than 2 years, this suggests a new team.
Management Team
Kim Rivers
CEO & Chairman
$150K
40
4.1 yrs
Mohan Srinivasan
Chief Financial Officer
$200K
66
Kevin Darmody
Chief Operating Officer
$150K
60
0.3 yrs
Jason Pernell
Chief Information Officer
$150K
42
Lynn Ricci
Director of Investor Relations
53
0.3 yrs
Eric Powers
General Counsel & Corporate Secretary
50
0.3 yrs
Victoria Walker
Director of Marketing & Community Relations
34
Steven Ferrell
Senior Human Resources Director
49
Timothy Morey
Director of Retail
56
Board of Directors Tenure
Average tenure and age of the Trulieve Cannabis board of directors in years:
- The tenure for the Trulieve Cannabis board of directors is about average.
Board of Directors
Kim Rivers
CEO & Chairman
$150K
40
Richard May
Director
41
3.7 yrs
Michael O’Donnell
Director
67
1.1 yrs
Thad Beshears
Director
44
3.7 yrs
George Hackney
Director
64
3.7 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Trulieve Cannabis's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Trulieve Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
TRUL News
Simply Wall St News
Trulieve Cannabis Corp. (CNSX:TRUL): What Can We Expect From This High Growth Stock?
Today I want to provide a brief commentary on how market analysts perceive Trulieve Cannabis's earnings growth outlook over the next couple of years and whether the future looks even brighter than the past. … View our latest analysis for Trulieve Cannabis Analysts' expectations for this coming year seems optimistic, with earnings rising by a significant 67%. … CNSX:TRUL Past and Future Earnings, May 21st 2019 Even though it is informative understanding the rate of growth each year relative to today’s value, it may be more valuable determining the rate at which the company is rising or falling on average every year.
Simply Wall St - – Full articleShould Trulieve Cannabis Corp. (CNSX:TRUL) Be Your Next Stock Pick?
Attractive stocks have exceptional fundamentals. … In the case of Trulieve Cannabis Corp. … financial health as well as
Simply Wall St - – Full articleShould We Be Delighted With Trulieve Cannabis Corp.'s (CNSX:TRUL) ROE Of 35%?
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … To keep the lesson grounded in practicality, we'll use ROE to better understand Trulieve Cannabis Corp. … That means that for every CA$1 worth of shareholders' equity, it generated CA$0.35 in profit.
Simply Wall St - – Full articleTrulieve Cannabis Corp. (CNSX:TRUL): Commentary On Fundamentals
As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as
Simply Wall St - – Full articleShould You Be Excited About Trulieve Cannabis Corp.'s (CNSX:TRUL) 35% Return On Equity?
To keep the lesson grounded in practicality, we'll use ROE to better understand Trulieve Cannabis Corp. … That means that for every CA$1 worth of shareholders' equity, it generated CA$0.35 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs Trulieve Cannabis Corp's (CNSX:TRUL) Balance Sheet Strong Enough To Weather A Storm?
Trulieve Cannabis Corp (CNSX:TRUL) is a small-cap stock with a market capitalization of CA$134m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes
Simply Wall St - – Full articleTRUL Company Info
Description
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 170 stock keeping units, including smokable flowers, flower pods for vaporizing, concentrates, topicals, capsules, tinctures, and vape cartridges. The company operates 26 stores. Trulieve Cannabis Corp. is headquartered in Quincy, Florida.
Details
| Name: | Trulieve Cannabis Corp. |
| TRUL | |
| Exchange: | CNSX |
| Founded: | |
| CA$1,492,290,320 | |
| 110,132,127 | |
| Website: | http://www.trulieve.com |
| Address: |
Trulieve Cannabis Corp. 6749 Ben Bostic Road, Quincy, Florida, 32351, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| CNSX | TRUL | Subordinate Votings Shares | Canadian National Stock Exchange | CA | CAD | 25. Sep 2018 | |
| OTCPK | TCNN.F | Subordinate Votings Shares | Pink Sheets LLC | US | USD | 25. Sep 2018 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/16 00:58 |
| End of day share price update: | 2019/07/15 00:00 |
| Last estimates confirmation: | 2019/07/11 |
| Last earnings filing: | 2019/05/28 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
